Sigilon Therapeutics Inc

NASDAQ:SGTX   3:59:51 PM EDT
5.00
-0.28 (-5.30%)
Products, Regulatory

Sigilon Therapeutics Announces Clinical Hold On Sig-001 Phase 1/2 Study In Hemophilia A

Published: 07/09/2021 11:59 GMT
Sigilon Therapeutics Inc (SGTX) - Sigilon Therapeutics Announces Clinical Hold on Sig-001 Phase 1/2 Study in Hemophilia A.
Sigilon Therapeutics Inc - Clinical Hold Was Initiated Following Company's Submission of a Serious Adverse Event.
Sigilon Therapeutics Inc - Clinical Hold Was Initiated Following Sae and Temporary Enrollment Halt to FDA and Other Regulatory Agencies.
Sigilon Therapeutics Inc - Status of Sae Investigation Will Continue to Be Reviewed by Safety Review Committee for Sig-001.